Heart failure in patients with coronary heart disease: Prevalence, characteristics and guideline implementation – Results from the German EuroAspire IV cohort

Caroline Morbach1,2, Martin Wagner1,3, Stefan Güntner1,2, Carolin Malsch1,3, Mehmet Oezkur1,4, David Wood5, Kornelia Kotseva5,6, Rainer Leyh6, Georg Ertl1,2, Wolfgang Karmann7, Peter U Heuschmann1,3 and Stefan Störk1,2*

Abstract

Background: Adherence to pharmacotherapeutic treatment guidelines in patients with heart failure (HF) is of major prognostic importance, but thorough implementation of guidelines in routine care remains insufficient. Our aim was to investigate prevalence and characteristics of HF in patients with coronary heart disease (CHD), and to assess the adherence to current HF guidelines in patients with HF stage C, thus identifying potential targets for the optimization of guideline implementation.

Methods: Patients from the German sample of the European Action on Secondary and Primary Prevention by Intervention to Reduce Events (EuroAspire) IV survey with a hospitalization for CHD within the previous six to 36 months providing valid data on echocardiography as well as on signs and symptoms of HF were categorized into stages of HF: A, prevalence of risk factors for developing HF; B, asymptomatic but with structural heart disease; C, symptomatic HF. A Guideline Adherence Indicator (GAI-3) was calculated for patients with reduced (≤40%) left ventricular ejection fraction (HFrEF) as number of drugs taken per number of drugs indicated; beta-blockers, angiotensin converting enzyme inhibitors/angiotensin receptor blockers, and mineralocorticoid receptor antagonists (MRA) were considered.

Results: 509/536 patients entered analysis. HF stage A was prevalent in n = 20 (3.9%), stage B in n = 264 (51.9%), and stage C in n = 225 (44.2%) patients; 94/225 patients were diagnosed with HFrEF (42%). Stage C patients were older, had a longer duration of CHD, and a higher prevalence of arterial hypertension. Awareness of pre-diagnosed HF was low (19%). Overall GAI-3 of HFrEF patients was 96.4% with a trend towards lower GAI-3 in patients with lower LVEF due to less thorough MRA prescription.

Conclusions: In our sample of CHD patients, prevalence of HF stage C was high and a sizable subgroup suffered from HFrEF. Overall, pharmacotherapy was fairly well implemented in HFrEF patients, although somewhat worse in patients with more reduced ejection fraction. Two major targets were identified possibly suited to further improve the implementation of HF guidelines: 1) increase patients’ awareness of diagnosis and importance of HF; and 2) disseminate knowledge about the importance of appropriately implementing the use of mineralocorticoid receptor antagonists.

(Continued on next page)
Background
Chronic heart failure (HF) is a grave condition with high prevalence, increasing incidence and severely compromised prognosis [1], (https://www.destatis.de/DE/Publikationen/Thematisch/Gesundheit/Gesundheitszustand/GesundheitInDeutschlandPublikation.pdf). Clinical guidelines on diagnosis and treatment of acute and chronic HF [2] translate the complexity of scientific research findings into recommendations for daily practice. Adherence to current HF guidelines has been shown to substantially reduce disease severity and HF related symptoms as well as to improve prognosis regarding rehospitalization and mortality [3–13].

Despite their widespread recognition, it remains a notoriously difficult challenge to implement guidelines in clinical practice [14–19]. Deficits include omission of beneficial therapy, suboptimal patient outcome, and waste of resources [20, 21]. Identification of barriers for guideline implementation [16, 22] in programs or clinical trials showed improvements in managing chronic HF [9, 11, 13, 17, 23, 24]. By contrast, in routine patient care disease specific therapy remains frequently insufficient [5, 8, 10, 16–18, 25, 26].

One of the major diagnoses contributing to HF is coronary heart disease (CHD) [27]. The European Action on Secondary and Primary Prevention by Intervention to Reduce Events (EuroAspire) IV survey evaluated the quality of secondary CHD prevention according to the Joint European Societies guidelines in everyday clinical practice across Europe [28].

The aim of the present study was 1) to determine the prevalence and characteristics of HF in the German patients enrolled in EuroAspire IV and 2) to assess the implementation of ESC guidelines on HF [2] in this cohort of usually cared CHD patients to identify potential targets for optimization of guideline adherence.

Methods
Patient cohort
We present data from the German hospital arm of EuroAspire IV [28]. Patients between 18 and 79 years of age with CHD were invited to attend a study visit if they had been hospitalized due to a coronary event (coronary artery bypass grafting (CABG), percutaneous coronary intervention (PCI), acute myocardial infarction, or myocardial ischemia, the latter two receiving conservative therapy without intervention) six to 36 months prior to the anticipated study visit. The study was approved by the ethics committee of the Medical Faculty, University of Würzburg (Vote 58/12), and all patients provided written informed consent.

Data collection
At the study visit (08/2012–03/2013), detailed information on medical history, medication, patient care, and behaviour was collected and physical examination (heart rate, weight, height, blood draw) was performed according to EuroAspire IV standards [28]. Information on the index event was collected by retrospective chart review [28]. Blood samples were processed, stored on-site, and analysed in batches. Selected parameters as lipid profile, glycosylated haemoglobin (HbA1c), and creatinine were analysed in the central EuroAspire IV Laboratory (Helsinki) [28].

In an additional heart failure module at the German study center, data on heart failure related symptoms were collected, and N-terminal pro-B-type natriuretic peptide (NT-proBNP) and high sensitive troponin T (hs-TnT) measured at the Central Laboratory of the University Hospital, Würzburg. During the face-to-face interview, patients were asked if they had ever been diagnosed with heart failure. The medical term (“Herzenssuffizienz”) and the German word (“Herzschwäche”) were explicitly mentioned and addressed by the interviewer. Angiography results of the index event were extracted from the hospital information system using the Comprehensive Heart Failure Center Data Warehouse [29]. When interpreting results from angiography reports, stenoses ≥50% were considered relevant.

Echocardiography
Echocardiography scans were performed by one experienced physician sonographer (SG) using a Vivid Q ultrasound scanner and a M4S transthoracic probe (GE Healthcare, Horten, Norway). The prespecified protocol adhered to recommendations formulated in current national and international guidelines [30–32]. All scans were stored digitally and analysed off-line (EchoPAC® PC Version 113; GE Healthcare, Buckinghamshire, Great Britain) by a European Association of Cardiovascular Imaging certified physician (CM) blinded to the patients’ history and study results. Left ventricular (LV) ejection fraction (EF) and LV end-diastolic volume were measured (Simpson’s biplane method, n = 428) or
visually estimated. Regional wall motion abnormalities were assessed using a 16 segment model. Valve regurgitation was determined by the colour Doppler multiplane vena contracta method, and valve stenosis was quantified by continuous wave Doppler measurements [31, 33, 34]. LV mass index was calculated (cube formula) based on M-Mode derived measurements of interventricular septum and posterior wall [30].

**Categorization of heart failure**

According to AHA/ACC guidelines [35], patients were grouped into stages of heart failure. To facilitate adequate categorization, the current guidelines emphasize the appropriate identification of "structural heart disease" [30, 36]. Accordingly, structural heart disease was diagnosed in the presence of at least one of the following: LV ejection fraction <50%, LV end-diastolic volume ≥ 97 mL/m², LV mass index >95 g/m² in females and ≥115 g/m² in men, any stenosis of mitral or aortic valve, regurgitation > mild of mitral or aortic valve, left atrial area ≥ 30 cm², septal e' < 8 cm/s, or lateral e' < 10 cm/s.

Heart failure related signs and symptoms included [37, 38] major criteria (paroxysmal nocturnal dyspnea, orthopnea, abnormal jugular venous distention, pulmonary rales, third heart sound) and minor criteria (ankle edema, night cough, dyspnea on exertion, hepatomegaly), while "symptomatic HF" was defined as 2 major or 1 major and 2 minor criteria being present concurrently [37, 38].

HF stage A was stated in the presence of risk factors for HF, but absence of both structural heart disease and HF related signs and symptoms. Stage B was defined as an asymptomatic patient at the study visit with documented structural heart disease. Stage C was assumed if a patient 1) already had or newly received the diagnosis of HF at discharge from index hospitalization; or was 2) symptomatic and had structural heart disease at the study visit. Stage C patients who had followed such advice. Adherence was assessed as number of patients who followed a given advice divided by the number of patients who had been given the respective advice.

**Cardiovascular risk factors and comorbidities**

Hypertension was defined as suggested by the German Society of Cardiology [35] as systolic blood pressure ≥ 140 mmHg or diastolic blood pressure ≥ 90 mmHg. Cut-off values differed for older or diabetic patients and those with chronic kidney disease [28].

**Implementation of guideline recommendations on pharmacotherapy**

Quality of guideline implementation in stage C patients was evaluated using the 2008 European Society of Cardiology Guidelines for the diagnosis and treatment of acute and chronic HF applicable at the time of the study visit [2]. The Guideline Adherence Indicator (GAI-3) was calculated (range 0%–100%) for each patient as number of drugs taken divided by number of drugs indicated considering indication and contraindication of beta-blockers, angiotensin converting enzyme inhibitors/angiotensin receptor blockers (ACEi/ARB), and mineralocorticoid receptor antagonists (MRA) [5, 7, 8, 12]: a) ACEi/ARB if LVEF ≤40% and New York Heart Association functional class (NYHA) I-IV, b) beta-blocker if LVEF ≤40% and NYHA II-IV or NYHA I and prior myocardial infarction, and c) MRA if LVEF ≤35% and NYHA III-IV but absence of major kidney dysfunction.

**Adherence to non-pharmacological advice**

In a structured interview, patients were asked if they had ever been given advice by a doctor or other health care professional regarding an increase in exercise, smoking cessation, or change of diet (sodium restriction, fat reduction, calorie restriction, eating more fish), and if they had followed such advice. Adherence was assessed as number of patients who followed a given advice divided by the number of patients who had been given the respective advice.

**Data analysis**

Statistical analysis was performed using SPSS (Version 23, SPSS Inc., Chicago, USA). Frequencies are reported as n (%) and quantitative data expressed as mean (standard deviation) or median (quartiles) depending on normality of distribution. We employed Q-Q plots to graphically check the normality assumption of individual variables. Univariable analyses across categories (e.g. HF stages, study visit vs. hospital discharge, LVEF groups) were performed using Fisher’s exact, ANCOVA or Kruskal-Wallis test, as appropriate. Two-sided p-values <0.05 were considered statistically significant. P-values were not corrected for multiple testing as the study was exploratory.

**Results**

Of the 536 patients enrolled at the German study center in 2012/13, 509 subjects had valid information on medical history, HF symptoms and echocardiographic results, and could be classified into stages of HF (Table 1): stage A, n = 20 (3.9%); stage B, n = 264 (51.9%); stage C, n = 225 (44.2%); 94 patients were diagnosed with HFrEF. Patients in higher HF stages were older (56 years in stage A, 67 years in stage B, 68 years in stage C), had a longer duration or CHD (2.0 years, 2.8 years, 2.9 years, respectively), were more likely to be hypertensive (15%, 49%, 42%, respectively), and suffered more often from chronic kidney disease (5%, 19%, 35%, respectively; all p for trend ≤0.007). Time since index event, the treatment
| Stage of Heart Failure | N (%) | Age (years), mean (SD) | Male sex, n (%) | Time since index event (months), mean (SD) | Index event | Affected vessels | Number of affected vessels | Duration of CHD (years), median (IQR) | Treatment for index event | Cardiovascular risk factors and comorbidities | Measurements |
|------------------------|-------|------------------------|----------------|--------------------------------------------|-------------|----------------|-----------------------|--------------------------------------|-----------------------|---------------------------------------------|--------------|
| A                      | 20 (3.9) | 56.3 (8.3) | 16 (80.0) | 20.4 (8.6) | Acute, n (%) | Main left coronary artery, n (%) | 1 | 2.0 (1.4–3.4) | Conservative, n (%) | Smoking*, n (%) |
| B                      | 264 (51.9) | 66.8 (8.2) | 221 (83.7) | 20.8 (9.1) | Primary CHD event, n (%) | LAD, n (%) | 2 | 2.8 (1.9–10.1) | CABIg, n (%) | Obesity*, n (%) |
| C                      | 225 (44.2) | 68.1 (9.1) | 180 (80.0) | 22.2 (8.7) | Acute, n (%) | Main left coronary artery, n (%) | 3 | 2.9 (2.0–9.9) | PCI, n (%) | LDL > = 2.6 mmol/L, n (%) |
|                         |          |                          |              |                                 | Primary CHD event, n (%) | LAD, n (%) |              |                          | Treatment for index event | Hypertension*, n (%) |
|                         |          |                          |              |                                 | CHD affected vessels, n (%) | RCX, n (%) |              |                          | Cardiovascular risk factors and comorbidities | Heart rate (min-1), median (IQR) |
|                         |          |                          |              |                                 | Number of affected vessels | RCA, n (%) |              |                          | Measurements | LDL Cholesterol (mmol/L), median (IQR) |
|                         |          |                          |              |                                 |              | 1 | 5 (52.9) | 9 (52.9) | 2.0 (1.4–3.4) | Smoking*, n (%) | BMI (kg/m2), median (IQR) |
|                         |          |                          |              |                                 | 2 | 6 (35.3) | 68 (30.9) | 2.8 (1.9–10.1) | Primary CHD event, n (%) | Systolic BP (mmHg), median (IQR) |
|                         |          |                          |              |                                 | 3 | 2 (11.8) | 44 (20.0) | 2.9 (2.0–9.9) | Treatment for index event | Diastolic BP (mmHg), median (IQR) |
|                         |          |                          |              |                                 | Number of affected vessels |              | 1 | 9 (52.9) | Hypertension*, n (%) | Heart rate (min-1), median (IQR) |
|                         |          |                          |              |                                 | 2 | 6 (35.3) | 68 (30.9) | 2.8 (1.9–10.1) | Cardiovascular risk factors and comorbidities | LDL Cholesterol (mmol/L), median (IQR) |
|                         |          |                          |              |                                 | 3 | 2 (11.8) | 44 (20.0) | 2.9 (2.0–9.9) | Measurements | HbA1c (%) |
|                         |          |                          |              |                                 | Number of affected vessels |              | 1 | 9 (52.9) | Smoking*, n (%) | Total protein (g/L), median (IQR) |
|                         |          |                          |              |                                 | 2 | 6 (35.3) | 68 (30.9) | 2.8 (1.9–10.1) | Primary CHD event, n (%) | HIA1c (%) |
|                         |          |                          |              |                                 | 3 | 2 (11.8) | 44 (20.0) | 2.9 (2.0–9.9) | Treatment for index event | Total protein (g/L), median (IQR) |
|                         |          |                          |              |                                 | Number of affected vessels |              | 1 | 9 (52.9) | Hypertension*, n (%) | HIA1c (%) |
|                         |          |                          |              |                                 | 2 | 6 (35.3) | 68 (30.9) | 2.8 (1.9–10.1) | Cardiovascular risk factors and comorbidities | Heart rate (min-1), median (IQR) |
|                         |          |                          |              |                                 | 3 | 2 (11.8) | 44 (20.0) | 2.9 (2.0–9.9) | Measurements | LDL Cholesterol (mmol/L), median (IQR) |

SD standard deviation, LAD left anterior descending coronary artery, RCX left circumflex coronary artery, RCA right coronary artery, CHD coronary heart disease, IQR interquartile range, CABIg coronary artery bypass graft, PCI percutaneous coronary intervention, LDL low density lipoprotein, BMI body mass index, HbA1c haemoglobin A1c, NT-proBNP N-terminal pro B-type natriuretic peptide, hs-TnT high-sensitive troponin T, BP blood pressure

1 ANCOVA
2 Fisher's exact test
3 Kruskal-Wallis test
*current smoker
BMI ≥ 30 kg/m2
5 systolic blood pressure ≥ 140 mmHg or diastolic blood pressure ≥ 90 mmHg or in patients with diabetes: systolic ≥ 140, diastolic ≥ 85 mmHg; >80 yrs: systolic ≥ 150, diastolic ≥ 90 mmHg, chronic kidney disease systolic ≥ 130, diastolic ≥ 90 mmHg
6 self reported or impaired fasting glucose or impaired glucose tolerance
7 glomerular filtration rate < 60 mL/min/kg
index hospitalization to the study visit (Table 3), there was a significant reduction in prescription frequency of MRA (13% vs. 8.4%) and beta-blocker (93% vs. 85%). A contra-indication was prevalent at the time of the study visit in 7 of 27 (26%) patients stopping beta-blocker; and in one of 18 (6%) patients stopping MRA therapy. NYHA class was not significantly different between LVEF categories, but patients with lower LVEF had significantly higher hs-TnT and NT-proBNP values. Prescription rates of beta-blocker and ACEi/ARB did not differ significantly, but patients with reduced LVEF were more often on MRA and diuretic medication (Table 4). In patients with HFrEF, quality of pharmacotherapy recommended by European guidelines applicable at the time of the study visit [2] varied markedly across substance classes: current pharmacotherapy fulfilled guideline recommendations [2] regarding ACEi/ARB in 86 (91.5%), regarding beta-blocker in 85 (90.4%), and regarding MRA in 4 (57%) HFrEF patients with the respective indication. Total GAI-3 was 96.4% (n = 87 with valid information on indication and contraindications of all three substance classes). No apparent difference in the quality of HF pharmacotherapy according to GAI-3 was detected between subjects treated predominantly by cardiologists vs general practitioners (p = 0.88).

One hundred and eighty-three (81%) stage C patients were on statin therapy. Of those, in 66 and 160 (36% and 87%) LDL levels were above 2.6 mmol/l and 1.8 mmol/l, respectively. Non-pharmacological advice regarding physical exercise, smoking cessation, sodium restricted diet, fat reduced diet, calory reduced diet, and a diet containing more fish was followed in 103 (70.1%), 13 (68.7%), 86 (81.9%), 115 (82.7%), 62 (66.7%), and 92 (79.3%) of respectively advised stage C patients. Patients,

Table 2 Echocardiographic measurements in all patients and according to heart failure stages

| Heart Failure Stage | Total | A | B | C | p |
|---------------------|-------|---|---|---|---|
| N (%)               | 509   | 20 (3.9) | 264 (51.9) | 225 (44.2) | <0.0011 |
| LVEF (%), median (IQR) | 58 (53–62) | 64 (58–67) | 59 (55–63) | 56 (50–61) | <0.0011 |
| LVEF categories, n (%) |       |     |     |     |    |
| < 30%               | 7 (1.4) | 0 | 2 (0.8) | 5 (2.3) | 0.0412 |
| 30–39%             | 23 (4.5) | 0 | 10 (3.8) | 13 (6.1) |    |
| 40–52%             | 80 (15.6) | 1 (5.0) | 32 (12.1) | 43 (20.1) |    |
| > 52%              | 402 (78.5) | 19 (95.0) | 220 (83.3) | 153 (71.5) |    |
| Wall motion abnormalities, n (%) | 138 (28.1) | 2 (10.0) | 59 (23.4) | 74 (35.7) | 0.0032 |
| LVEDVI (ml/m²), median (IQR) | 60 (50–72) | 49 (40–56) | 60 (50–69) | 61 (53–79) | <0.0011 |
| LV mass index (g/m²), median (IQR) | 93 (78–110) | 82 (64–95) | 92 (77–108) | 99 (82–120) | <0.0011 |
| LAA (cm²), median (IQR) | 20 (17–23) | 18 (16–20) | 20 (17–23) | 20 (17–24) | 0.0381 |
| E/e’, median (IQR) | 9 (7.2–11.4) | 6.8 (5.5–8.4) | 8.8 (7.2–10.8) | 9.5 (7.5–12.1) | <0.0011 |

LV left ventricle, EF ejection fraction, IQR interquartile range, LVEDVI LV end-diastolic volume index, LAA left atrial area, E/e’ LV filling index (transmitral inflow velocity to annular velocity ratio)

1Kruskal-Wallis test
2Fisher’s exact test
who were aware of having heart failure, followed non-pharmacological advice more often compared to unaware patients (exercise 72.4% vs. 69.0%; smoking 100% vs. 81.8%; sodium restricted diet 79.2% vs. 82.5%; fat reduced diet 82.2% vs. 82.4%; calory reduced diet 90.5% vs. 58.6%; diet containing more fish 77.8% vs. 79.8%).

**Discussion**

Prevalence and characteristics of HF in CHD

In this German sample of the EuroAspire IV cohort of patients hospitalized for CHD within the previous six to 36 months, we found a high prevalence of HF stages B and C. Patients in HF stage C were older, had a longer duration of CHD and were more likely to suffer from hypertension and chronic kidney disease. We could not observe associations between HF stage and the urgency or therapy of the index CHD event that classified for participation in EuroAspire IV, or the affected coronary vessels. Although HF stage C patients exhibited more regional wall motion abnormalities, a majority of stage C patients presented with preserved LVEF and the median LVEF was still in the normal range.

It is reassuring, that only a minority of patients with a coronary event requiring hospital admission had HF with reduced ejection fraction. This, at least in parts, might be due to the optimization of emergency pre-hospital and in-hospital care and improved treatment options preventing extensive myocardial damage [39]. On the other hand this highlights the importance of arterial hypertension in patients with CHD, which was the most important risk factor for HF stage C in our sample (along with chronic kidney disease, which again is predominantly caused by arterial hypertension [40]). Hypertension is an established independent risk factor for CHD in all populations accounting for approximately 47% of ischemic events [40, 41]. It further represents a major component in the progression of left ventricular

**Table 3** Pharmacotherapy of patients in HF stage C at discharge and at the study visit

|                     | Discharge | Study visit | p   |
|---------------------|-----------|-------------|-----|
| Beta blocker, n (%) | 210 (93.3)| 191 (84.9)  | 0.002|
| ACEI/ARB, n (%)     | 197 (87.6)| 187 (83.1)  | 0.154|
| MRA, n (%)          | 30 (13.3) | 19 (8.4)    | 0.043|
| Loop diuretic, n (%)| 66 (29.3) | 72 (32.0)   | 0.451|
| Thiazide diuretic, n (%) | 35 (15.6) | 42 (18.7) | 0.382|
| Glycoside, n (%)    | 12 (5.3)  | 14 (6.2)    | 0.625|

N = 225, age 68.1 (9.1) years, males 180 (80%)

ACEI/ARB angiotensin-converting-enzyme inhibitor/angiotensin-receptor blocker, MRA mineralocorticoid receptor antagonist

1Fisher’s exact test

**Table 4** Characteristics, measurements and pharmacotherapy of patients in HF stage C at the study visit according to left ventricular ejection fraction

| Left ventricular ejection fraction | <40% | 40–52% | >52% | p   |
|-----------------------------------|------|--------|------|-----|
| N (%)                             | 18 (8.4) | 43 (20.1) | 153 (71.5) | 0.409|
| Age year, mean (SD)               | 69 (8.6) | 69 (9.3) | 67 (9.2) | 0.001|
| Males, n (%)                      | 17 (94.4) | 36 (83.7) | 117 (76.5) | 0.162|
| NYHA class, n (%)                 | 5 (29.4) | 9 (21.4) | 53 (35.1) | 0.104|
| I                                 | 5 (29.4) | 9 (21.4) | 53 (35.1) | 0.104|
| II                                | 5 (29.4) | 9 (21.4) | 53 (35.1) | 0.104|
| III                               | 5 (29.4) | 9 (21.4) | 53 (35.1) | 0.104|
| IV                                | 2 (11.8) | 1 (2.4) | 2 (1.3) | 0.049|
| Hs-TnT, median (IQR)              | 14.3 (8.6–22.9) | 12.3 (8.1–17.8) | 8.9 (6.7–13.0) | 0.001|
| NT-proBNP, median (IQR)           | 783 (371.5–1960.5) | 495 (255.5–1061.8) | 189 (86.5–401.0) | <0.001|
| Beta blocker, n (%)               | 18 (100) | 38 (88.4) | 125 (81.7) | 0.085|
| ACEI/ARB, n (%)                   | 16 (88.9) | 36 (83.7) | 125 (81.7) | 0.872|
| MRA, n (%)                        | 3 (16.7) | 7 (16.3) | 7 (4.6) | 0.011|
| Loop diuretic, n (%)              | 12 (66.7) | 21 (48.8) | 35 (22.9) | <0.001|
| Thiazide diuretic, n (%)          | 2 (11.1) | 1 (2.3) | 37 (24.2) | 0.001|
| Glycoside, n (%)                  | 3 (16.7) | 4 (9.3) | 7 (4.6) | 0.074|

N = 225, age 68.1 (9.1) years, males 180 (80%)

NYHA New York Heart Association functional class, Hs-TNT high sensitive troponin T, NT-proBNP N-terminal pro B-type natriuretic peptide, ACEI/ARB angiotensin-converting-enzyme inhibitor/angiotensin-receptor blocker, MRA mineralocorticoid receptor antagonist, GAI-3 Guideline Adherence Indicator: number of drugs indicated divided by number of drugs prescribed according to 2008 ESC HF guideline [2]

1ANCOVA
2Fisher’s exact test
3Kruskal-Wallis test
dysfunction into symptomatic HF [40]. With increased LV mass, enlarged left atrium, diastolic dysfunction and preserved LVEF, a substantial part of our stage C patients showed the typical echocardiographic signs of hypertensive heart disease indicating a co-existence of both, CHD and hypertensive heart disease. Physicians, caring for CHD patients, should be aware of the high likelihood of HF with preserved LVEF in those patients. Further prospective studies are needed to investigate the distinct pathogenesis of asymptomatic myocardial dysfunction aggravating into symptomatic HF [42] and to clarify the importance of aggressive blood pressure control in this special patient collective.

**Guideline adherence in stable chronic CHD patients**

Although the diagnosis of HF was clearly stated in the discharge letter of the index hospital stay in the majority of stage C patients, only about one fifth of these patients were aware of this diagnosis at the study visit interview. The majority of stage C patients exhibited preserved LVEF at the study visit; in these patients evidence to support HF treatment is limited. However, a substantial number of patients had had impaired LVEF at the index event or had reduced LVEF at the time of the study visit thus meeting the criteria for the diagnosis of HFrEF and qualifying to apply guidelines for pharmacotherapy. HF related pharmacotherapy followed guideline recommendations in a substantial part of HFrEF patients. There was a trend towards lower GAI-3 in patients with lower LVEF, mainly due to lower rates of MRA prescription. Compared to discharge pharmacotherapy, significant changes in medication had occurred at the study visit with less frequent prescription of beta-blocker and MRA, which could only in part be explained by contraindications prevalent at the study visit. There was no association between GAI-3 at study visit and main caregiver within the previous 3 months.

Guideline adherence in treatment of HF has been shown to substantially improve patients’ prognosis regarding morbidity, rehospitalization, and mortality [3–7, 9, 12, 13]. The MAHLER study defined a guideline adherence indicator (GAI-3) concerning the three prognostic relevant substances beta-blockers, ACEi/ARB, and MRA [7]. GAI-3 was highly predictive of favourable changes of LVEF and LV end-diastolic diameter [9], frequency of and time to hospitalization for HF [7], and survival [5, 9, 10, 12].

Although an improved guideline adherence over the past decades has been suggested (https://www.destatis.de/DE/Publikationen/Thematisch/Gesundheit/Gesundheitszustand/GesundheitInDeutschlandPublikation.pdf), [4, 13, 23], guideline implementation and long-term adherence remain challenging (https://www.destatis.de/DE/Publikationen/Thematisch/Gesundheit/Gesundheitszustand/GesundheitInDeutschlandPublikation.pdf), [15, 18, 25]. Recent data from 15 randomly chosen general practitioners in the metropolitan region of Hamburg, Germany, showed high prescription rate of ACEi/ARB (76%), beta-blockers (73%), and MRA (18%) in outpatients with chronic HF [43]. However, after collective review of patient records and subsequent counselling, prescription rates could further be improved (ACEi/ARB: 87%, beta-blocker: 84%), and GAI-3 increased from 22% to 56% [43].

In our study sample, we found comparable prescription rates of MRA but higher rates for beta-blockers and ACEi/ARB. This might, at least in part, be due to the fact, that all patients had a hospital stay within the previous 3 years and had been discharged with optimized pharmacotherapy. Further, beta-blockers as ACEi/ARB also constitute corner stones in the treatment of both CHD and hypertension. Nevertheless, we observed that MRA were prescribed at lower than desired frequency, in particular regarding the time interval from hospital discharge to the study visit, and lower GAI-3 in patients with more reduced LVEF at the time of the study visit due to lower prescription rates of MRA. Since this observation is based on small numbers, it awaits corroboration in larger samples. The hesitation to prescribe MRA might be due to the higher likelihood of potential adverse events requiring a closer patient monitoring, but also because the importance of MRA regarding favourable prognosis may have not yet sufficiently transferred to the outpatient setting [43].

Non-pharmacological advice [2] regarding physical exercise, smoking cessation, and a healthy diet was followed in a substantial part of stage C patients. Further, as part of secondary prevention for CHD, four fifth of stage C patients were on statin therapy and CHD treatment goals were reached in about two thirds of these patients. Although lipid lowering therapy is a corner stone in the secondary prevention of CHD, it should be carefully reviewed in patients with symptomatic HF as there is no evidence for statins improving the prognosis of patients with symptomatic HF [2], and lower total cholesterol has been shown to be associated with increased mortality in HF patients [44].

Overall, our numbers suggest successful implementation of HF guideline recommendations in usual patient care, similarly for general practitioners and cardiologists, although there is still room for improvement.

Deficient patients’ awareness of their disease is one of the major problems in the implementation of guidelines. The low awareness of previously documented HF, assessed in the context of an interview, in our study sample is in line with the findings of a contemporary, multinational convenience sample of subjects attending the HF Awareness Day Initiatives in 2013 revealing low
awareness of HF and its typical signs and symptoms in the lay public as well as important misconceptions regarding the importance and the prognostic implications of HF [45]. The German National Disease Management Guideline “Chronic Heart Failure” [27] as well as the Guideline on HF of the German Society of Primary Care [46] highlight the importance of information about and acceptance of the own disease for therapy adherence. Therefore, programs to increase knowledge about and how to live with the disease as well as potential involvement of family members into patient care are essential [27, 46].

Our study showed a fairly high, but still not sufficient level of implementation and subsequent adherence to current HF guidelines in patients with CHD and chronic HF. These results suggest that increasing patients’ awareness of their diagnosis and importance of HF as well as spreading the knowledge about the importance of MRA in the pharmacotherapy of chronic HF may be promising targets for the improvement of guideline implementation.

Limitations
Our sample might represent a best practice scenario due to its selection, but our data still indicate that efforts into the direction of guideline implementation are feasible. Selection might have occurred in favour of more compliant patients attending the study [28], but our study participation selection process did not take influence on the main caregiver. Further, there were a few patients with an LVEF <30% but without signs and symptoms of HF. Although signs of HF were assessed very carefully at the study visit, HF related symptoms could only be assessed by self-reporting, i.e. no technical method was used (such as spiroergometry) to objectify dyspnoea on exertion. Nevertheless, assessment of the Framingham criteria is a common and well evaluated method to assess HF and has shown high diagnostic and prognostic accuracy [37, 38]. Regarding guideline-adherence, only contraindications prevalent at the time of the study visit could be taken into account. Further, the total number of aware patients was too small to reliably investigate the association between awareness and non-adherence to guidelines.

Conclusions
In the German EuroAspire IV sample of CHD patients, we found a high prevalence of both asymptomatic HF stage B and overt HF stage C. A majority of stage C patients had a preserved ejection fraction and revealed hypertension and chronic kidney disease as major HF-related factors. Although pharmacotherapy of HFrEF patients fairly well complied with current HF guidelines in patients with higher LVEF, its implementation was worse in patients with more reduced LVEF. We identified two major targets to optimize guideline implementation: 1) to increase the patients’ awareness of the diagnosis and importance of HF and 2) to spread the knowledge about the prognostic impact of MRA in the pharmacotherapy of chronic HF.

Abbreviations
ACC: American College of Cardiology; ACEi: Angiotensin converting enzyme inhibitor; AHA: American Heart Association; ARB: Angiotensin receptor blocker; CABG: Coronary artery bypass grafting; ESC: European Society of Cardiology; EuroAspire: European Action on Secondary and Primary Prevention by Intervention to Reduce Events survey; CHD: Coronary heart disease; GAI: Guideline adherence indicator; HbA1c: Glycosylated haemoglobin A1c; HF: Heart failure; hSTNT: High sensitive troponin T; LV: Left ventricle; LVEF: Left ventricular ejection fraction; MRA: Mineralocorticoid receptor antagonist; NT-proBNP: N-terminal pro B-type natriuretic peptide; NYHA: New York Heart Association functional class; PCI: Percutaneous coronary intervention

Acknowledgements
We thank the participants of the German EUROASPIRE IV survey for providing their data. We are thankful to all nurses, assistants, students, data managers and physicians at the recruiting centers for their time and effort on data collection. We gratefully acknowledge the support of A. Adamska (Dept. of Cardiovascular Medicine, National Heart and Lung Institute, Imperial College London, UK) for administrative assistance and M. Glomet and M. Konte (EURObservationalResearch Programme, European Heart House, Sophia-Antipolis, France) for data-management assistance within the EURO-ASPIRE IV survey. Parts of the results have been presented at the Scientific meeting of the European Society of Cardiology 2016. This publication was funded by the German Research Foundation (DFG) and the University of Wuerzburg in the funding programme Open Access Publishing.

Funding
The EuroAspire IV survey was carried out under the auspices of the European Society of Cardiology, EURObservational Research Programme and was supported by grants to the ESC from Amgen (EUROPE) GmbH, AstraZenecaAB, BMS/AstraZeneca, F. Hoffmann La Roche, GlaxoSmithKline PLC and Merck&Co. The researchers were independent of the funders who had no influence on study design, data collection, data analysis, data interpretation, decision to publish, or writing the manuscript. Data collection at the German EuroAspire IV study center was supported by the German Heart Foundation as well as by the German Ministry of Education and Research (BMBF) within the Comprehensive Heart Failure Center Wuerzburg (BMBF 01EO1004 and 01EO1504).

Availability of data and materials
The datasets generated and/or analysed during the current study are property of the European Society of Cardiology and are not publicly available.

Authors’ contributions
All authors contributed to the conception of the study and CM, MW, SG, DW, KK, StS, PUH contributed to study design. CM, MW, SG, MO, RL, GE, WK, StS, PUH contributed to data acquisition, CM, MW, CMa, PUH, StS contributed to data analysis, and CM, MW, CMa, MO, DW, KK, RL, GE, WK, PUH, StS contributed to data interpretation. CM, MW, PUH, StS drafted and all other authors critically revised the manuscript. All authors read and approved the final manuscript.

Competing interests
KK and DW had grant support from the European Society of Cardiology; KK received travel grants from Roche and Boehringer Ingelheim, StS reports research grants from the German Ministry of Education and Research, European Union, University Hospital Wuerzburg; participation in Data Safety Monitoring and Event Adjudication Boards in trials sponsored by ROCHE and MEDTRONIC; principal investigator in trials (co-)sponsored by BOEHRINGER, NOVARTIS, BAYER, LUNDBECK; speaker honoraria by BOEHRINGER, SERIVER, NOVARTIS, ASTRA-ZENECA, PFIZER, BAYER. PUH reports research grants from
the German Ministry of Research and Education, European Union, Charité, Berlin Chamber of Physicians, German Parkinson Society, University Hospital Würzburg, Robert-Koch-Institute, Charité–Universitätsmedizin Berlin (within MonoDAFS), MonoDAFS is supported by an unrestricted research grant to the Charité from Bayer, University Göttingen (within FIND-AF-randomized; FIND-AF-randomized is supported by an unrestricted research grant to the University Göttingen from Boehringer-Ingelheim), and University Hospital Heidelberg (within RASUNOA-prime; RASUNOA-prime is supported by an unrestricted research grant to the University Hospital Heidelberg from Bayer, BWS, Boehringer-Ingelheim, Daichii Sankyo), outside submitted work. All other authors have nothing to disclose relevant for the submitted work.

Consent for publication
Not applicable.

Ethics approval and consent to participate
All patients provided written informed consent to take part in the study. The Ethics approval and consent to participate Not applicable.

Consent for publication
Authors have nothing to disclose relevant for the submitted work.

Acknowledgments
Research grant to the University Hospital Heidelberg from Bayer, BMS, (within RASUNOA-prime; RASUNOA-prime is supported by an unrestricted research grant to the University Hospital of Göttingen from Boehringer-Ingelheim), and University Hospital Heidelberg Charité from Bayer), University Göttingen (within FIND-AF-randomized; FIND-AF-randomized is supported by an unrestricted research grant to the Germans competence network heart failure. Clin Res Cardiol. 2012;101(4):263–72. doi:10.1007/s00392-011-0388-y.

Frankenstein L, Remppis F, Angermann CE, Katus HA, Ertl GE, Stork S. Implementation of pharmacotherapy guidelines in heart failure experience from the German competence network heart failure. Clin Res Cardiol. 2012;101(4):263–72. doi:10.1007/s00392-011-0388-y.

Goder G, Stork S, Gelbrich G, Brenner S, Deubner N, Morbach C, Wallenborn J, Berliner D, Ertl GE, Angermann CE. Nurse-coordinated collaborative disease management improves the quality of guideline-recommended heart failure therapy, patient-reported outcomes, and left ventricular remodelling. Eur J Heart Fail. 2015;17(4):442–52. doi:10.1002/ejhf.252.

Postel G, Altenberger J, Pacher R, Ebner CH, Weiser M, Winter A, Fruhwald F, Dorrau Ns, Ehmsen U, Reiter S, Steinerich A, Eder V, Boehmer A, Pilgerdoscher L, Ablasser K, Kerox O, Groebner H, Auer J, Jakl G, Hallas A, Ess M, Ulmer H, Austrian Working Group on Heart F. Does matter! Optimisation of guideline adherence is associated with lower mortality in stable patients with chronic heart failure. Int J Cardiol. 2014;175(1):83–9. doi:10.1016/j.ijcard.2014.04.255.

Nakanå, A, Johnsen SP, Frederiksen BL, Svendsen ML, Agger C, Schodt I, Eustrip K. Trends in quality of care among patients with incident heart failure in Denmark 2003–2010: a nationwide cohort study. BMC Health Serv Res. 2013;13:391. doi:10.1186/1472-6963-13-391.

Gagliardi AR, Alhabib S, members of Guidelines International Network Implementation Working Group. Trends in guideline implementation: a scoping systematic review. Implement Sci. 2015;10:54. doi:10.1186/s13024-015-0247-8.

Zak-Golab A, Holecki M, Smertka M, Chudek J. Do primary care physicians follow the current recommendations for hypertensive pharmacotherapy? Pol Arch Med Wewn. 2013;123(S):206–14.

Karbach U, Schubert I, Hagemeister J, Ernstmnn N, Pfaff H, Hopf HW. Physicians’ knowledge of and compliance with guidelines: an exploratory study in cardiovascular diseases. Dtsch Arztebl Int. 2011;108(5):1–9. doi:10.3238/arztebl.2011.0061.

Braun V, Heintze C, Rufer V, Welke J, Stein T, Mehrhof F, Dini L. Innovative strategy for implementing chronic heart failure guidelines among family physicians in different healthcare settings in Berlin. Eur J Heart Fail. 2011; 13(11):93–9. doi:10.1093/eurjhf/hfq181.

Franco G, Biagio F, Battista ZG, De Simone A, Stabile G, Bossone E, Bosio G, Sacca L, Oliviero U, Investigators A-H, ALERT-HF: adherence to guidelines in the treatment of patients with chronic heart failure. J Cardiovasc Med (Hagerstown). 2014;15(6):491–7. doi:10.2459/JCM.000000000000038.

Jullièrer Y, Suty-Selton C, Riant E, Darraç JP, Dellinger A, Labarre JP, Druelle J, Mulek G, Danchin N, Joudain P, participants Oc. Prescription of cardiovascular drugs in the French ODIN cohort of heart failure patients according to age and type of chronic heart failure. Arch Cardiovasc Dis. 2014;107(1):32–7. doi:10.1016/j.acvd.2013.11.001.

Greenhalgh T, Howick J, Maskey N, Evidence Based Medicine Renaissance G. Evidence based medicine: a movement in crisis? BMJ. 2013;343:g3725. doi:10.1136/bmj.g3725.

Pronovost PJ. Enhancing physicians’ use of clinical guidelines. JAMA. 2013;310(23):2501–2. doi:10.1001/jama.2013.281834.

Peters-Klimm F, Natanzon I, Muller-Tasch T, Ludt S, Nikendel C, Lossnitzer N, Szczesny J, Herzog W, Junger J. Barriers to guideline implementation and educational needs of general practitioners regarding heart failure: a qualitative study. GMS Z Med Ausbild. 2012;29(3):Doc46. doi:10.3205/zma00816.
